Showing results (131-140 of 142) with videos related to
Sort By:
Pageof 15
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.Blood|March 4, 2017
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β productionJing Du, Katelyn Paz, Ryan Flynn, et al.Research and Practice in Thrombosis and Haemostasis|December 17, 2024
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2019
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaSairah Ahmed, Jennifer A Kanakry, Kwang W Ahn, et al.Journal of Thrombosis and Haemostasis : JTH|April 13, 2024
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ABella Madan, Margareth C Ozelo, Priyanka Raheja, et al.Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.Journal of Thrombosis and Haemostasis : JTH|September 7, 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, et al.The Lancet. HIV|July 11, 2020
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility studyChristine M Durand, Adam A Capoferri, Andrew D Redd, et al.Pageof 15